Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis Mulleman

Showing results (51-60 of 98) with videos related to

Pageof 10
Sort By:
Clinical Pharmacokinetics|December 14, 2017
Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough ConcentrationDavid Ternant, Christophe Passot, Alexandre Aubourg, et al.
RMD Open|November 18, 2021
Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trialsJohan Law-Wan, Marc-Antoine Sparfel, Sophie Derolez, et al.
Therapeutic Drug Monitoring|July 12, 2011
Therapeutic drug monitoring of infliximab in spondyloarthritis: an observational open-label studyJean-Camille Méric, Denis Mulleman, Emilie Ducourau, et al.
Epidemiology and Infection|October 6, 2021
Large increase of vertebral osteomyelitis in France: a 2010-2019 cross-sectional studyYoann Conan, Emeline Laurent, Yannick Belin, et al.
Arthritis and Rheumatism|February 28, 2009
Effect of hyaluronic acid in symptomatic hip osteoarthritis: a multicenter, randomized, placebo-controlled trialPascal Richette, Philippe Ravaud, Thierry Conrozier, et al.
Orphanet Journal of Rare Diseases|August 10, 2023
Joint manifestations revealing inborn metabolic diseases in adults: a narrative reviewAmaury Loret, Claire Jacob, Saloua Mammou, et al.
Basic & Clinical Pharmacology & Toxicology|October 6, 2025
Quality Assessment of Therapeutic Drug Monitoring Assays of Therapeutic Antibodies Across Europe: An UpdateJames Bluett, Merita Rumano, María José Martínez Becerra, et al.
Mabs|September 3, 2016
The underlying inflammatory chronic disease influences infliximab pharmacokineticsChristophe Passot, Denis Mulleman, Theodora Bejan-Angoulvant, et al.
Clinical Pharmacokinetics|August 14, 2025
Immunoglobulin G Receptors (FcγR), in Addition to Target-Antigen and Neonatal Fc Receptor (FcRn), Influence Rituximab PharmacokineticsDavid Ternant, Olivier Le Tilly, Guillaume Cartron, et al.
Annals of the Rheumatic Diseases|February 20, 2014
Towards an individualised target concentration of adalimumab in rheumatoid arthritisEmilie Ducourau, David Ternant, Thierry Lequerré, et al.
Pageof 10

Showing results (51-60 of 98) with videos related to

Sort By:
Pageof 10
Clinical Pharmacokinetics|December 14, 2017
Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough ConcentrationDavid Ternant, Christophe Passot, Alexandre Aubourg, et al.
RMD Open|November 18, 2021
Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trialsJohan Law-Wan, Marc-Antoine Sparfel, Sophie Derolez, et al.
Therapeutic Drug Monitoring|July 12, 2011
Therapeutic drug monitoring of infliximab in spondyloarthritis: an observational open-label studyJean-Camille Méric, Denis Mulleman, Emilie Ducourau, et al.
Epidemiology and Infection|October 6, 2021
Large increase of vertebral osteomyelitis in France: a 2010-2019 cross-sectional studyYoann Conan, Emeline Laurent, Yannick Belin, et al.
Arthritis and Rheumatism|February 28, 2009
Effect of hyaluronic acid in symptomatic hip osteoarthritis: a multicenter, randomized, placebo-controlled trialPascal Richette, Philippe Ravaud, Thierry Conrozier, et al.
Orphanet Journal of Rare Diseases|August 10, 2023
Joint manifestations revealing inborn metabolic diseases in adults: a narrative reviewAmaury Loret, Claire Jacob, Saloua Mammou, et al.
Basic & Clinical Pharmacology & Toxicology|October 6, 2025
Quality Assessment of Therapeutic Drug Monitoring Assays of Therapeutic Antibodies Across Europe: An UpdateJames Bluett, Merita Rumano, María José Martínez Becerra, et al.
Mabs|September 3, 2016
The underlying inflammatory chronic disease influences infliximab pharmacokineticsChristophe Passot, Denis Mulleman, Theodora Bejan-Angoulvant, et al.
Clinical Pharmacokinetics|August 14, 2025
Immunoglobulin G Receptors (FcγR), in Addition to Target-Antigen and Neonatal Fc Receptor (FcRn), Influence Rituximab PharmacokineticsDavid Ternant, Olivier Le Tilly, Guillaume Cartron, et al.
Annals of the Rheumatic Diseases|February 20, 2014
Towards an individualised target concentration of adalimumab in rheumatoid arthritisEmilie Ducourau, David Ternant, Thierry Lequerré, et al.
Pageof 10